 | |
| Clinical data | |
|---|---|
| Trade names | Corectim |
| Other names | JTE-052; JTE-052A |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C16H18N6O |
| Molar mass | 310.361 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. [1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. [1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema. [2]
Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases. [3]
In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Anzupgo (delgocitinib), a medicine intended for the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate. [4] [5] The applicant for this medicinal product is LEO Pharma A/S. [4]
- ^ a b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi: 10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.
- ^ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
- ^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi: 10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.
- ^ a b "Anzupgo EPAR". European Medicines Agency. 25 July 2024. Retrieved 25 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (Press release). 25 July 2024. Retrieved 29 July 2024.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| Trade names | Corectim |
| Other names | JTE-052; JTE-052A |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C16H18N6O |
| Molar mass | 310.361 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. [1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. [1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema. [2]
Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases. [3]
In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Anzupgo (delgocitinib), a medicine intended for the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate. [4] [5] The applicant for this medicinal product is LEO Pharma A/S. [4]
- ^ a b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi: 10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.
- ^ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
- ^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi: 10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.
- ^ a b "Anzupgo EPAR". European Medicines Agency. 25 July 2024. Retrieved 25 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (Press release). 25 July 2024. Retrieved 29 July 2024.
|
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |